Fidia Pharma USA INC. announces expansion into regenerative medicine markets with launch of NUDYN™
The first product in the new Fidia Orthobiologics Portfolio, result of a scientifically developed manufacturing process
FLORHAM PARK, N.J.–(BUSINESS WIRE)– Fidia, a world leader in the research, development, and manufacturing of hyaluronic acid (HA)-based products, is introducing NuDYN™, its first product in the regenerative medicine category.
NuDYN™ is a shelf-stable, injectable, flowable amniotic membrane-derived allograft from donated placentas obtained via cesarean delivery. It is processed to be acellular to allow for shelf-stable storage while retaining the beneficial intrinsic properties of the amniotic membrane including hyaluronic acid, collagen, and growth factors. These natural properties of the allograft provide benefits of protection, lubrication, and support.